Details of the Drug
General Information of Drug (ID: DM9ICSA)
Drug Name |
1,2,3,4,6-penta-O-galloyl-D-glucopyranose
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
D-Glucopyranose, pentakis(3,4,5-trihydroxybenzoate); 40410-94-4; 1,2,3,4,6-pentakis-o-(3,4,5-trihydroxybenzoyl)-d-glucopyranose; AC1L4RL6; SCHEMBL675693; AC1Q62I0; DTXSID00193426; 2,3,4,5,6-Pentagalloylglucose; BDBM175525; 3-O-Digalloyl-1,2,6-trigalloylglucose; 1,2,3,4,6-penta-O-galloyl--d-glucopyranose; US9120744, CDE-001 (or 073); 1-O,2-O,3-O,4-O,6-O-Pentagalloyl-D-glucopyranose; D-Glucose, 2,3,4,5,6-pentakis(3,4,5-trihydroxybenzoate); [(2R,3R,4S,5R)-3,4,5,6-tetrakis[(3,4,5-trihydroxybenzoyl)oxy]oxan-2-yl]methyl 3,4,5-
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL is unavailable | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 4 | Molecular Weight (mw) | 945.7 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 16 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 15 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 26 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||